Trending NewsTrending NewsNASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $11.03 -0.95 (-7.93%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$11.26 +0.24 (+2.13%) As of 05/15/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.00▼$11.9350-Day Range$8.02▼$12.1552-Week Range$6.72▼$20.56Volume166,661 shsAverage Volume325,096 shsMarket Capitalization$204.36 millionP/E RatioN/ADividend YieldN/APrice Target$42.33Consensus RatingModerate Buy Company Overview Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders. Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation. The company has also received orphan drug and Fast Track designations for lenabasum in systemic sclerosis and dermatomyositis, underscoring regulatory recognition of its potential to address conditions with limited treatment options. Corbus continues to explore additional indications for its pipeline operations, seeking partnerships and collaborations to support late-stage development and eventual commercialization. Founded in 2006 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals primarily serves patients in North America and Europe through its clinical trial network. Under the leadership of President and Chief Executive Officer Kenneth T. Leonard and Chief Financial Officer Robert J. Conway, the company remains focused on advancing innovative therapies for complex inflammatory diseases and positioning itself as a leader in resolution pharmacology.AI Generated. May Contain Errors. Read More Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCRBP MarketRank™: Corbus Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 483rd out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialCorbus Pharmaceuticals has a consensus price target of $42.33, representing about 283.8% upside from its current price of $11.03.Amount of Analyst CoverageCorbus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.83) to ($6.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.23% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 4.61.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 4.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.90 News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest4 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBP Stock News HeadlinesCorbus Pharmaceuticals (NASDAQ:CRBP) & Lexeo Therapeutics (NASDAQ:LXEO) Head-To-Head SurveyMay 17 at 5:37 AM | americanbankingnews.comCorbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at GuggenheimMay 16 at 3:38 AM | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 17 at 1:00 AM | Banyan Hill Publishing (Ad)Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsMay 14 at 8:00 AM | globenewswire.comCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comCorbus Pharmaceuticals Reports FDA Alignment and Positive Developments for CRB-701 and CRB-913 ProgramsMay 12, 2026 | quiverquant.comQCorbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate UpdateMay 12, 2026 | globenewswire.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Passes Above Fifty Day Moving Average - Should You Sell?May 12, 2026 | americanbankingnews.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $8.14 at the beginning of the year. Since then, CRBP stock has increased by 35.5% and is now trading at $11.03. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($1.23) EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $0.03. When did Corbus Pharmaceuticals IPO? Corbus Pharmaceuticals (CRBP) raised $20 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 20,206,636 shares at $1.00 per share. Who are Corbus Pharmaceuticals' major shareholders? Top institutional investors of Corbus Pharmaceuticals include Orbimed Advisors LLC (9.38%), Renaissance Technologies LLC (1.87%), Dimensional Fund Advisors LP (0.77%) and Assenagon Asset Management S.A. (0.48%). Insiders that own company stock include Yuval Cohen, Dominic Smethurst, Sean F Moran, Ian Hodgson, Anne Altmeyer and John Kenneth Jenkins. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings5/12/2026Today5/17/2026RBC Capital Markets Global Healthcare Conference 20265/19/2026Jefferies Global Healthcare Conference 20266/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 2 days ago, CRBP's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBP CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees40Year Founded2009Price Target and Rating Average Price Target for Corbus Pharmaceuticals$42.33 High Price Target$54.00 Low Price Target$28.00 Potential Upside/Downside+283.8%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($5.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.89% Return on Assets-61.78% Debt Debt-to-Equity RatioN/A Current Ratio7.92 Quick Ratio8.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.82 per share Price / Book1.62Miscellaneous Outstanding Shares18,528,000Free Float17,880,000Market Cap$204.36 million OptionableOptionable Beta2.68 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CRBP) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts